GSK (GSK) announced that the European Medicines Agency, EMA, has accepted for review the regulatory application of a prefilled syringe presentation of Shingrix for the prevention of shingles. The new prefilled syringe removes the need to reconstitute separate vials prior to administration, offering an alternative option for physicians, pharmacists and other healthcare professionals who administer vaccinations. The current presentation of the vaccine consists of a lyophilised, powder, antigen and a liquid adjuvant, which healthcare professionals combine prior to administering. The new presentation has the same composition as the reconstituted vaccine and the submission is based on data demonstrating comparability between the two.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- GSK Pharma call volume above normal and directionally bullish
- GSK’s Jemperli Gains Expanded EU Approval for Endometrial Cancer
- GSK announces expanded EU approval in endometrial cancer for Jemperli combo
- Sector Spotlight: Big Pharma will push to pause Medicare drug price negotiations
- Novo Nordisk’s (NYSE:NVO) Ozempic and Wegovy Lined Up for Medicare Drug Price Negotiations